{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/antimuscarinics/","result":{"pageContext":{"chapter":{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics","depth":2,"htmlHeader":"<!-- begin field d7d88ee3-80e2-422a-bfe6-e16b292523cb --><h2>Antimuscarinics (anticholinergics)</h2><!-- end field d7d88ee3-80e2-422a-bfe6-e16b292523cb -->","summary":"","htmlStringContent":"<!-- begin item cd05ac0b-e345-4ee6-a5ef-520b515fa82f --><!-- end item cd05ac0b-e345-4ee6-a5ef-520b515fa82f -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8c4b2dc0-e463-5030-bc20-55cd7096a6ef","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 542ffbc4-db16-4cc3-87e8-f73187e794b3 --><h3>What are the contraindications and cautions for antimuscarinics?</h3><!-- end field 542ffbc4-db16-4cc3-87e8-f73187e794b3 -->","summary":"","htmlStringContent":"<!-- begin item abf4b63a-8c93-4493-948e-91523e462bec --><!-- begin field b2353194-89c0-4580-b943-d60a36efbe56 --><ul><li><strong>Do not prescribe an antimuscarinic drug to people with:</strong><ul><li>Gastrointestinal obstruction or intestinal atony.</li><li>Myasthenia gravis.</li><li>Paralytic ileus.</li><li>Prostatic enlargement.</li><li>Pyloric stenosis.</li><li>Severe ulcerative colitis.</li><li>Significant bladder outflow obstruction or urinary retention.</li><li>Toxic megacolon.</li><li>Severe hepatic impairment — manufacturer advises caution for oxybutynin; flavoxate can be used.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>Do not prescribe solifenacin</strong> to people with narrow-angle glaucoma.</li><li><strong>Do not prescribe flavoxate</strong> to people with gastro-intestinal haemorrhage.</li><li><strong>Do not prescribe propiverine</strong> to people with:<ul><li>Moderate to severe hepatic impairment.</li><li>Uncontrolled angle-closure glaucoma.</li><li>Tachyarrhythmias.</li></ul></li><li><strong>Do not prescribe trospium </strong>to people with tachyarrhythmias.</li><li><strong>Avoid modified-release preparations of tolterodine</strong> in people with:<ul><li>Hepatic impairment. </li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>). </li></ul></li></ul></li><li><strong>Prescribe an antimuscarinic drug with caution to:</strong><ul><li>People with:<ul><li>Acute myocardial infarction.</li><li>Arrhythmias — may be worsened.</li><li>Autonomic neuropathy.</li><li>Cardiac insufficiency or cardiac surgery — due to association with tachycardia.</li><li>Conditions characterized by tachycardia.</li><li>Congestive heart failure or coronary artery disease — may be worsened.</li><li>Diarrhoea.</li><li>Gastro-oesophageal reflux disease.</li><li>Hiatus hernia with reflux oesophagitis.</li><li>Hypertension.</li><li>Hyperthyroidism — due to association with tachycardia.</li><li>Prostatic hyperplasia.</li><li>Pyrexia.</li><li>Ulcerative colitis.</li><li>Mild to moderate hepatic impairment — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/antimuscarinics/#dose-initiation-titration\">Doses</a> for recommended dosage adjustments in people with hepatic impairment.</li><li>Renal impairment — use oxybutynin with caution; no dosage adjustment is needed with darifenacin and flavoxate; other antimuscarinics require dosage adjustment if the eGFR is less than 30 mL/minute/1.73 m<sup>2</sup>. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/antimuscarinics/#dose-initiation-titration\">Doses</a> for recommended dosage adjustments in people with renal impairment.</li></ul></li><li>Elderly people (especially if frail).</li><li>People susceptible to angle-closure glaucoma.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>Prescribe oxybutynin with caution</strong> in people with acute porphyrias.</li><li><strong>Prescribe solifenacin with caution</strong> in people with:<ul><li>Neurogenic bladder disorder.</li><li>Susceptibility to QT-interval prolongation.</li></ul></li><li><strong>Prescribe tolterodine with caution</strong> in people with history of QT-interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field b2353194-89c0-4580-b943-d60a36efbe56 --><!-- end item abf4b63a-8c93-4493-948e-91523e462bec -->","subChapters":[]},{"id":"f708f908-b99d-557b-99af-b24308fc7962","slug":"dose-initiation-titration","fullItemName":"Dose - initiation and titration","depth":3,"htmlHeader":"<!-- begin field 77b26859-62e2-4f71-bbc8-60de8a3721d7 --><h3>How should I start and titrate an antimuscarinic drug?</h3><!-- end field 77b26859-62e2-4f71-bbc8-60de8a3721d7 -->","summary":"","htmlStringContent":"<!-- begin item aab1f459-842b-4ba9-b2d2-72ba38d3e6c9 --><!-- begin field daf5977e-3b84-4ca5-afed-6f0c4f471e5c --><ul><li><strong>The recommended doses are:</strong><ul><li><strong>Oxybutynin immediate-release preparations </strong>— initially 5 mg two to three times a day, increased if necessary up to 5 mg four times a day.<ul><li>In elderly people, prescribe initially 2.5–3 mg twice daily, increased if tolerated to 5 mg twice daily, adjusted according to response.</li><li>Use with caution in renal and hepatic impairment.</li></ul></li><li><strong>Oxybutynin modified-release preparations </strong>— initially 5 mg once daily, increased in steps of 5 mg every week, adjusted according to response; maximum 20 mg a day.<ul><li>Use with caution in renal and hepatic impairment.</li></ul></li><li><strong>Oxybutynin transdermal patch</strong> — one patch twice a week.<ul><li>Patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3–4 days and site replacement patch on a different area. The same area should be avoided for 7 days.</li><li>Use with caution in renal and hepatic impairment.</li></ul></li><li><strong>Darifenacin modified-release</strong> <strong>preparations </strong>— initially 7.5 mg once daily, increased if necessary to 15 mg after 2 weeks.<ul><li>Prescribe a maximum of 7.5 mg daily in moderate hepatic impairment; avoid in severe hepatic impairment.</li></ul></li><li><strong>Fesoterodine modified-release preparations </strong>— 4 mg once daily, increased if necessary up to 8 mg once daily.<ul><li>Increase dose cautiously in mild hepatic impairment; maximum daily dose of 4 mg in moderate hepatic impairment.</li><li>Increase dose cautiously in mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–80 mL/minute/1.73m<sup>2</sup>); maximum daily dose of 4 mg in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Flavoxate</strong> <strong>immediate-release preparations </strong>— 200 mg three times a day.</li><li><strong>Propiverine immediate-release preparations </strong>(for urinary frequency, urgency and incontinence associated with overactive bladder) — 15 mg once or twice a day, increased if necessary up to 15 mg three times a day.<ul><li>Use with caution in mild hepatic impairment; avoid in moderate to severe hepatic impairment.</li><li>Prescribe a maximum of 30 mg a day in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>); use with caution in mild to moderate avoid in renal impairment (eGFR 30–80 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Propiverine modified-release preparations </strong>(for urinary frequency, urgency and incontinence associated with overactive bladder) — 30 mg once a day.<ul><li>Use with caution in mild hepatic impairment; avoid in moderate to severe hepatic impairment.</li><li>Prescribe a maximum of 30 mg a day in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>); use with caution in mild to moderate avoid in renal impairment (eGFR 30–80 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Solifenacin immediate-release preparations </strong>— 5 mg once daily, increased if necessary to 10 mg once daily.<ul><li>Prescribe a maximum of 5 mg daily in moderate hepatic impairment; avoid in severe hepatic impairment.</li><li>Prescribe a maximum of 5 mg a day in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Tolterodine immediate-release preparations </strong>— 2 mg twice daily, reduced if not tolerated to 1 mg twice daily.<ul><li>Reduce dose to 1 mg twice daily in hepatic impairment.</li><li>Reduce dose to 1 mg twice daily in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Tolterodine modified-release preparations </strong>— 4 mg once daily.<ul><li>Avoid in hepatic impairment.</li><li>Avoid in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Trospium immediate-release preparations </strong>— 20 mg twice daily, to be taken before food.<ul><li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment.</li><li>Reduce dose to 20 mg once daily or 20 mg on alternate days in severe renal impairment (eGFR less than 30 mL/minute/1.73m<sup>2</sup>).</li></ul></li><li><strong>Trospium modified-release preparations </strong>— 60 mg once daily.<ul><li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment.</li><li>Avoid Regurin<sup>®</sup> XL in renal impairment.</li></ul></li></ul></li><li>Review the person every 4–6 weeks until symptoms are stable, and then every 6–12 months. Assess symptoms, quality-of-life, adverse effects, and the need for continuing treatment.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field daf5977e-3b84-4ca5-afed-6f0c4f471e5c --><!-- end item aab1f459-842b-4ba9-b2d2-72ba38d3e6c9 -->","subChapters":[]},{"id":"281e8ae5-f185-5e56-a952-3a17ce49b172","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ac5675cb-2541-4c69-840e-fc0962432058 --><h3>What are the adverse effects of antimuscarinics?</h3><!-- end field ac5675cb-2541-4c69-840e-fc0962432058 -->","summary":"","htmlStringContent":"<!-- begin item 01d01fd4-1124-4bca-99e1-63608979511a --><!-- begin field 5ae23990-3717-4e17-9af3-2d15274b7dbb --><ul><li><strong>Adverse effects of antimuscarinics are common, and elderly or frail people may be more susceptible.</strong><ul><li>The impact of adverse effects can be reduced by using a small starting dose and titrating the dose slowly. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/antimuscarinics/#dose-initiation-titration\">Initiation and titration</a> for more information.</li><li>If unacceptable adverse effects persist, reduce the dose or stop treatment with the antimuscarinic drug.</li></ul></li><li><strong>Adverse effects of antimuscarinic drugs include:</strong><ul><li>Common or very common — constipation, dizziness, drowsiness, dry mouth, dyspepsia, flushing, headache, nausea, palpitations, skin reactions, tachycardia, urinary disorders, vision disorders, and vomiting.</li><li>Rare or very rare — confusion (more common in elderly).</li></ul></li><li><strong>In addition for oxybutynin:</strong><ul><li>With oral use:<ul><li>Common or very common — diarrhoea and dry eyes.</li><li>Uncommon — abdominal discomfort, appetite decreased, and dysphagia.</li><li>Frequency not known — angioedema, anxiety, arrhythmia, cognitive disorder, depressive symptom, drug dependence, gastrointestinal disorders, glaucoma, hallucination, heat stroke, hypohidrosis, mydriasis, nightmare, paranoia, photosensitivity reaction, seizure, and urinary tract infection (UTI).</li></ul></li><li>With transdermal use:<ul><li>Common or very common — gastrointestinal discomfort and increased risk of infection.</li><li>Uncommon — back pain and injury.</li></ul></li></ul></li><li><strong>In addition for darifenacin:</strong><ul><li>Common or very common — abdominal pain, dry eye, and nasal dryness.</li><li>Uncommon — asthenia, bladder pain, cough, diarrhoea, dyspnoea, erectile dysfunction, flatulence, hyperhidrosis, hypertension, increased risk of infection, injury, insomnia, oedema, oral ulceration, taste altered, thinking abnormal, and urinary tract disorder.</li><li>Frequency not known — angioedema.</li></ul></li><li><strong>In addition for fesoterodine:</strong><ul><li>Common or very common — diarrhoea, dry eye, gastrointestinal discomfort, insomnia, and throat complaints.</li><li>Uncommon — altered taste, cough, fatigue, gastrointestinal disorders, nasal dryness, UTI, and vertigo.</li><li>Rare or very rare — angioedema.</li></ul></li><li><strong>In addition for propiverine:</strong><ul><li>Common or very common — abdominal pain and fatigue.</li><li>Uncommon — altered taste and tremor.</li><li>Rare or very rare — restlessness.</li><li>Frequency not known — hallucination.</li></ul></li><li><strong>In addition for solifenacin:</strong><ul><li>Common or very common — gastrointestinal discomfort.</li><li>Uncommon — altered taste, cystitis, dry eye, dry throat, fatigue, gastrointestinal disorders, nasal dryness, peripheral oedema, and UTI.</li><li>Rare or very rare — angioedema and hallucination.</li><li>Frequency not known — anaphylactic reaction, arrhythmias, decreased appetite, delirium, dysphonia, glaucoma, hyperkalaemia, liver disorder, muscle weakness, QT interval prolongation, and renal impairment.</li></ul></li><li><strong>In addition for tolterodine:</strong><ul><li>Common or very common — abdominal pain, bronchitis, chest pain, diarrhoea, dry eye, fatigue, gastrointestinal disorders, paraesthesia, peripheral oedema, vertigo, and weight gain.</li><li>Uncommon — arrhythmia, heart failure, memory loss, and nervousness.</li><li>Frequency not known — angioedema and hallucination.</li></ul></li><li><strong>In addition for trospium:</strong><ul><li>Common or very common — abdominal pain.</li><li>Uncommon — chest pain, diarrhoea, and flatulence.</li><li>Rare or very rare — arthralgia, asthenia, dyspnoea, and myalgia.</li><li>Frequency not known — agitation, anaphylactic reaction, angioedema, hallucination, and severe cutaneous adverse reactions (SCARs).</li></ul></li><li><strong>In addition for flavoxate:</strong><ul><li>Frequency not known — angioedema, diarrhoea, dysphagia, eosinophilia, fatigue, hyperpyrexia, hypersensitivity, leucopenia, nervousness, and vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]​​​​​​</p><!-- end field 5ae23990-3717-4e17-9af3-2d15274b7dbb --><!-- end item 01d01fd4-1124-4bca-99e1-63608979511a -->","subChapters":[]},{"id":"bcfa1a9d-2572-500f-a762-5eec452f6257","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6e413732-b95d-4d75-94bd-6bb18e472f90 --><h3>What are the key drug interactions of antimuscarinics?</h3><!-- end field 6e413732-b95d-4d75-94bd-6bb18e472f90 -->","summary":"","htmlStringContent":"<!-- begin item c4df9960-245b-41b8-ae3f-c9f6b713982d --><!-- begin field f0c143b1-15e7-46ff-a1aa-9e1ba4e62a16 --><ul><li><strong>Drug interactions of antimuscarinics include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li><strong>Other drugs with antimuscarinic action </strong>— concurrent use of antimuscarinic drugs with other drugs with antimuscarinic action (such as tricyclic antidepressants and sedating antihistamines) will cause additive adverse effects.</li><li><strong>Antiarrhythmic drugs </strong>— tolterodine should not be given to people taking antiarrhythmic medication due to the increased risk of ventricular arrhythmias.</li><li><strong>Potent CYP3A4 inhibitors</strong> — darifenacin, fesoterodine, solifenacin, and tolterodine are metabolized by the cytochrome P450 enzyme CYP3A4. For people also taking a potent CYP3A4 inhibitor (such as clarithromycin, itraconazole, or ritonavir):<ul><li>Concurrent use with darifenacin is contraindicated.</li><li>Most manufacturers advise against concurrent use with tolterodine.</li><li>Manufacturers advise adjusting the dose of solifenacin and fesoterodine.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of the individual antimuscarinic drug, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field f0c143b1-15e7-46ff-a1aa-9e1ba4e62a16 --><!-- end item c4df9960-245b-41b8-ae3f-c9f6b713982d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}